Should Type 2 Diabetes Management Be More of a Priority in Post-Acute Coronary Syndrome Patients? - European Medical Journal

This site is intended for healthcare professionals

Continue

Should Type 2 Diabetes Management Be More of a Priority in Post-Acute Coronary Syndrome Patients?

Diabetes
Download PDF

This symposium took place on 14th September 2015 as part of the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden

Chairperson:
Ele Ferrannini 1
Speakers:
Ele Ferrannini , 1 Stephen J Nicholls , 2 Jørgen Rungby , 3 Jean-Claude Tardif , 4 Faiez Zannad 5

1. University of Pisa School of Medicine, Pisa, Italy
2. SAHMRI and University of Adelaide, Adelaide, Australia
3. Gentofte University Hospital, Hellerup, Copenhagen, Denmark
4. Montreal Heart Institute Research Centre, Montreal, Quebec, Canada
5. Université de Lorraine and CHU, Vandoeuvre-lès-Nancy, France

Acknowledgements:

Writing assistance was provided by Dr Janet R. Davies, Atlantic Medical Writing, and funded by Takeda Pharmaceuticals International GmbH Limited.

Citation:
EMJ Diabet. ;3[1]:31-38. DOI/10.33590/emjdiabet/10310596. https://doi.org/10.33590/emjdiabet/10310596.
Support:

The symposium was organised by Takeda Pharmaceuticals International GmbH. All authors received honoraria for the preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily of Takeda Pharmaceuticals International GmbH.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

This symposium aimed to address the current issues in the management of patients with Type 2 diabetes (T2D) post-acute coronary syndrome (ACS), bringing together the views of both cardiologists and diabetologists. T2D increases the risk of ACS and is associated with a poorer prognosis for these patients. Although guidelines provide comprehensive recommendations for patients with ACS, specific guidance is lacking following hospital discharge for those with concomitant T2D. As a result, these patients receive suboptimal treatment compared with patients without T2D. The cardiovascular (CV) benefits of intensive glucose lowering alone for those with T2D are uncertain. However, knowledge of the CV safety profiles of available therapies helps diabetologists to provide individualised treatment for their patients. Currently, three studies have reported on the CV safety of dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with T2D. However, active inclusion of patients who are both post-ACS (15–90 days) and at high risk of CV disease (CVD) is rare. Only the DPP-4 alogliptin has been assessed in a CV safety outcome study in patients with this specific profile.

Please view the full content in the pdf above.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.